1Colquitt JL, Green C, Sidhu MK, et al. Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes, Health Technology Assessment 2004;8:43.
2Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: a meta-analysis. Diabetes Care 2003; 26:1079 - 1087.
3Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials, BMJ 2002; 324: 705.
4Pickup J, Keen H. Continuous subcutaneous insulin infusion at25 Years, Diabetes Care 2002 ;25: 593 - 598.
5Plotnick LP, Clark LM, Brancat FL, et al. Safety and effectiveness of insulin pump therapy in children and adolescents with type 1 diabetes. Diabetes Care 2003; 26:1142 - 1146.
6Hanas R. Selection for and initiat ion of continuous subcutaneous insulin infusion. Horm Res 2002;57(suppl 1):101- 104.
7Simmons D, Thompson CF, Conroy C, et al. Use of insulin pumps in pregnancies complicated by type 2 diabetes and gestational diabetes in a multiethnic community, Diabetes Care 2001; 24:2078 -2082.
8Steel JM, Johnstone FD, Hume R, et al. Insulin requirements during pregnancy in women with type 1 diabetes. Obstet Gynecol1994; 83: 253 - 258.
3Weng J , Li Y, Xu W, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial [J]. Lancet ,2008,371 (9626) : 1753 -1760.
4Rizzo MR, Barbieri M, Marfella R, et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase- N inhibition[J]. Diabetes Care ,2012,35 (10) :2076 - 2082.
5Ceriello A, Esposito K, Piconi L, et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients [J] . Diabetes, 2008 , 57 ( 5) : 1349 - 1354.
6Torimoto K, Okada Y, Mori H, et al. Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus [J] . Cardiovasc Diabetol,2013 ,12: 1.
7Zhou J, Li H, Ran X, et al. Reference values for continuous glucose monitoring in Chinese subjects [ J ]. Diabetes Care, 2009,32 ( 7 ) : 1188 - 1193.
8Barbieri M, Rizzo MR, Marfella R, et al. Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP- N inhibitors [J] . Atherosclerosis, 2013,227(2) :349 -354.
9Hong ES, Khang AR, Y oon JW , et al. Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study [J ]. Diabetes Obes Metab,2012,14(9) :795 -802.
10Vilsboll T, Rosenstock J, Yki-Jarvinen H, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes[J]. Diabetes Obes Metab,2010,12(2) :167 -177.
